Cargando…

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy

BACKGROUND: Paraneoplastic hyperleucocytosis (PH) is sporadically seen in patients with advanced solid tumors. CASE PRESENTATION: We report a female patient with disseminated melanoma metastases. Two days after the first dosage of combined immunotherapy using the cytotoxic T lymphocyte antigen-4 (CT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gambichler, Thilo, Stockfleth, E., Susok, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208032/ https://www.ncbi.nlm.nih.gov/pubmed/30376886 http://dx.doi.org/10.1186/s40425-018-0430-y

Ejemplares similares

Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
por: Gambichler, Thilo, et al.
Publicado: (2017)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2020)

Hyperleucocytosis as an unusual presentation of hypereosinophilic pneumonitis with acute respiratory distress syndrome
por: Alshehri, Saleh Saad, et al.
Publicado: (2022)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Multivariate analysis of prognostic factors in patients with nodular melanoma
por: Susok, L., et al.
Publicado: (2021)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma
por: Susok, Laura, et al.
Publicado: (2021)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
por: Melian, Marcos, et al.
Publicado: (2018)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
por: Hantel, Andrew, et al.
Publicado: (2018)

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
por: McDonald, Marin A., et al.
Publicado: (2018)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
por: Fujimura, Taku, et al.
Publicado: (2018)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
por: Furudate, Sadanori, et al.
Publicado: (2016)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Comparison of the Skin Cancer Quality of Life Impact Tool and the Skin Cancer Index Questionnaire in Measurement of Health-Related Quality of Life and the Effect of Patient Education Brochures in Patients with Actinic Keratosis, Non-melanoma Skin Cancer, and Cutaneous Melanoma
por: El Abbadi, Sam, et al.
Publicado: (2021)

Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results
por: Gambichler, Thilo, et al.
Publicado: (2019)

Correction to: Comparison of the Skin Cancer Quality of Life Impact Tool and the Skin Cancer Index Questionnaire in Measurement of Health-Related Quality of Life and the Effect of Patient Education Brochures in Patients with Actinic Keratosis, Non-melanoma Skin Cancer, and Cutaneous Melanoma
por: El Abbadi, Sam, et al.
Publicado: (2021)

Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
por: SAKAGUCHI, Yuri, et al.
Publicado: (2020)

Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma
por: Wix, Sophia, et al.
Publicado: (2023)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma
por: Kijima, Yu, et al.
Publicado: (2021)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

Advances in Targeting Cutaneous Melanoma
por: Kasakovski, Dimitri, et al.
Publicado: (2021)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes
por: Gambichler, Thilo, et al.
Publicado: (2022)

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
por: Amaral, Teresa, et al.
Publicado: (2020)

Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
por: Fujimura, Taku, et al.
Publicado: (2020)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
por: Meyers, D. E., et al.
Publicado: (2018)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy
por: Minami, Keisuke, et al.
Publicado: (2021)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
por: Ma, Vincent T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_si5bfacnd777njjlfcog3q2p8q